logo
Hospitals Lose Supreme Court Case: Key Implications for DSH Patients

Hospitals Lose Supreme Court Case: Key Implications for DSH Patients

Forbes29-04-2025
WASHINGTON, DC - OCTOBER 07: United States Supreme Court (front row L-R) Associate Justice Sonia ... More Sotomayor, Associate Justice Clarence Thomas, Chief Justice of the United States John Roberts, Associate Justice Samuel Alito, and Associate Justice Elena Kagan, (back row L-R) Associate Justice Amy Coney Barrett, Associate Justice Neil Gorsuch, Associate Justice Brett Kavanaugh and Associate Justice Ketanji Brown Jackson pose for their official portrait at the East Conference Room of the Supreme Court building on October 7, 2022 in Washington, DC. The Supreme Court has begun a new term after Associate Justice Ketanji Brown Jackson was officially added to the bench in September. (Photo by)
n a 7-2 decision, the Supreme Court ruled against hospitals in Advocate Christ Medical Center v. Kennedy, addressing how to account for patients in Disproportionate Share Hospitals (DSHs). A DSH serves a high volume of low-income, Medicaid-eligible and uninsured patients, receiving special payments to offset uncompensated care costs.
The case, led by Advocate Christ Medical Center in Oak Lawn, Illinois, and joined by over 200 hospitals, sought to clarify patient eligibility for enhanced DSH payments. Plaintiff hospitals argued they were entitled to additional DSH payments for any patient eligible for Supplemental Security Income (SSI), a federal program supporting low-income disabled, blind, or elderly individuals. However, Medicare, represented as Secretary Robert F. Kennedy Jr, maintained that only patients actively receiving SSI cash payments should count, excluding those merely eligible or enrolled.
This distinction impacts billions in Medicare payments to hospitals serving low-income populations. Associate Justices Ketanji Brown Jackson and Sonia Sotomayor dissented, advocating for broader eligibility. The ruling reinforces stricter criteria for DSH calculations, potentially straining hospital finances, particularly for safety-net systems. As healthcare costs rise, this decision underscores ongoing tensions between federal policy, hospital reimbursement and healthcare's growing dependency on government reimbursement for fiscal solvency.
Commonly known as safety-net hospitals, physicians at DSHs treat a significant proportion of low-income, Medicaid-eligible, and uninsured patients, often at an academic trauma center. For these patients, alternative care options are frequently unavailable.
Mandated by federal law, Medicaid programs provide DSH payments to qualifying hospitals to ensure financial stability and maintain access to care for vulnerable populations. This was established during the 1985 Consolidated Omnibus Budget Reconciliation Act, the DSH program uses a formula based on the hospital's DSH patient percentage, which includes Medicare patients receiving Supplemental Security Income and Medicaid-eligible inpatient days.
These facilities incur significant financial losses caring for underserved populations, and DSH payments supplement reimbursements to support their operation.
It's not a trivial program. In 2021, Medicaid DSH payments totaled $18.9 billion, funded by federal and state contributions
Supplemental Security Income (SSI) is a federal program administered by the Social Security Administration that provides monthly financial assistance to individuals with limited income and resources who are disabled, blind, or aged 65 and older. SSI aims to ensure a minimum income for basic needs like food, clothing, and shelter. Eligibility requires meeting income and asset limits, and disability must prevent substantial gainful activity. In 2025, the maximum federal SSI payment is $967 for an individual and $1,450 for a couple.
In essence, the federal government has established a formula to assess the proportion of indigent patients served by a health system. This determines eligibility for DSH payments.
The DSH patient percentage is the sum of two fractions: the Medicaid fraction and the Medicare/SSI fraction. The formula looks at what percentage of the total patients treated are Medicaid eligible and what percentage of Medicare patients treated received SSI payments. These are indicators for low-income patients.
Generally, a hospital qualifies for DSH payments if the DSH patient percentage exceeds 15% or meets state-specific threshold. There some nuances, but that's the broad policy strokes.
Hospitals reported losses exceeding $1.5 billion annually in DSH payments from 2006 to 2009 due to restrictive patient accounting methods. This interpretation creates an estimated 15% payment shortfall based on eligibility criteria. The Supreme Court's ruling in Advocate Christ Medical Center v. Kennedy upheld two lower court decisions, reinforcing that DSH calculations should include only patients actively receiving SSI cash payments. In 2022, the U.S. District Court for the District of Columbia ruled in favor of the government, a decision affirmed by the U.S. Court of Appeals for the District of Columbia.
The legal consensus centers on the variability of SSI eligibility, which depends on monthly income and assets. Justice Amy Coney Barrett, writing for the majority, explained, 'Recipients must apply and be deemed eligible for benefits, and eligibility can fluctuate monthly based on income and resources.'
This dynamic underscores why only active SSI recipients are counted, aligning with federal policy to ensure precise DSH funding allocation. The ruling, while clarifying eligibility, may exacerbate financial challenges for safety-net hospitals serving low-income populations.
Hospitals are increasingly reliant on government funding for fiscal solvency, a trend perhaps warned by Frederick Hayek et al. Safety-net facilities face significant financial strain, prompting strategic responses. Immediate tactics will include lobbying Congress to delay DSH cuts, adopting value-based care models and perhaps enhancing operational efficiencies through digital tools and artificial intelligence. Leveraging the 340B Drug Pricing Program offers another avenue to offset losses. Rising labor costs further complicate finances, hospitals were certainly look to curb that growth. It's importance to recognize that a large majority of physicians are now employees of DSHs, not independent providers. Will they be caught up in the downward pressure on hospital labor costs?
At it's core, stakeholders must closely monitor the sector for ripple effects, such as reduced services or closures, which could disproportionately impact low-income communities.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eli Lilly's 170% UK price hike for Mounjaro is just the start as pharma firms bow to Trump's pricing pressures
Eli Lilly's 170% UK price hike for Mounjaro is just the start as pharma firms bow to Trump's pricing pressures

CNBC

time8 minutes ago

  • CNBC

Eli Lilly's 170% UK price hike for Mounjaro is just the start as pharma firms bow to Trump's pricing pressures

Eli Lilly 's move to raise the U.K. list price of its blockbuster diabetes drug Mounjaro marks the start of prices hikes across Europe, analysts say, as pharmaceutical firms respond to U.S. President Donald Trump's drug pricing demands. Lilly said Thursday that it had reached an agreement with the U.K. government to raise the list price of its weekly injection from Sept. 1, while maintaining access for patients covered by the publicly funded National Health Service (NHS). The U.S. pharma giant said it is now working with some other governments to adjust prices by the start of next month, without providing details of the specific countries involved. Analysts expect other firms to follow suit. "Lilly doing this isn't shocking and I think that we'll see more to come," Kavita Patel, NBC News & MSNBC medical contributor and Stanford University professor, told CNBC's "Fast Money" on Thursday. President Trump earlier this month delivered an ultimatum to pharma firms as part of his ongoing campaign to stamp out what he deems as unfair pricing practices in the U.S. In letters sent to 17 major pharmaceutical firms, the president outlined the steps they must take by Sept. 29 to lower the price of U.S. prescription drugs to "most favored nation" (MFN) levels. Lilly's pricing decision takes the U.K. list price of its popular treatment from a range of £92 (about $124.57) to £122 a month, depending on the dose size, to between £133 and £330 — a 170% price jump. That compares to its U.S. list price of $1,079.77 a month, before insurance and other rebates. The U.S. consistently pays the most in the world for many prescription drugs, due in part to the country's highly complex and fragmented reimbursement system, and a lack of the types of national pricing control prevalent in much of Europe. Several European pharma firms have spoken out in support of the White House's pricing demands, with AstraZeneca CEO Pascal Soriot saying last month that Trump was "right" to push for price equalization. Novartis CEO Vas Narasimhan has cited "productive" conversations with the administration, while Roche Chief Executive Thomas Schinecker has suggested that U.S. prices could be cut in half if the government removed intermediaries, known as pharmacy benefit managers (PBMs). Stanford University's Patel noted that firms like Eli Lilly may also be willing to accede to Trump's pricing demands as they seek coverage for their weight loss drugs under forthcoming changes to the U.S. government's Medicare and Medicaid health insurance systems for low-income people and retirees. "The United States is their big market and having that share in both Medicare and Medicaid is everything for drugs like Mounjaro. So this is important and I don't think they'll be the only one that we see," she said. Indeed, rival diabetes and obesity drug giant Novo Nordisk is seeking to regain ground in the lucrative U.S. market after a series of missteps and supply shortages have seen it lose market share to both Lily and other cheaper compounded weight loss drugs. Novo Nordisk 's Chief Financial Officer Karsten Munk Knudsen said earlier this month that Trump's drug pricing demands had "resonated" with the company and that it was already lowering the price of its Wegovy and Ozempic treatments stateside. The company said Monday that it would reduce the cost of Ozempic for cash-paying patients to $499 per month, less than half of its monthly U.S. list price. Nevertheless, Knudsen previously suggested that it could be difficult to simultaneously raise prices in other markets, given stretched public finances and strict pharmaceutical price caps across Europe. "If we look ex-U.S. markets, there's rather limited history in terms of raising prices … I believe it will be challenging to significantly raise prices outside the U.S.," he told CNBC's "Squawk Box Europe." Industry bodies, meanwhile, have warned of the damaging impact sudden prices hikes could have on patient care if implemented to meet Trump's Sept. 29 deadline. Already, U.K. private pharmacies have reported a surge in orders for Lilly's Mounjaro following Thursday's announcement. "Short notice changes to pricing for medicines such as this also have a serious effect on access to an important public health service and pharmacy business themselves," Henry Gregg, chief executive of the U.K.'s National Pharmacy Association, said in a statement. "We are urging the manufacturers to ensure that pharmacies are treated equitably and that proper support is in place," he added.

TD Cowen Reiterates Buy Rating on Molina Healthcare (MOH) Stock
TD Cowen Reiterates Buy Rating on Molina Healthcare (MOH) Stock

Yahoo

time7 hours ago

  • Yahoo

TD Cowen Reiterates Buy Rating on Molina Healthcare (MOH) Stock

Molina Healthcare, Inc. (NYSE:MOH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 28, Ryan Langston, an analyst from TD Cowen, reiterated a 'Buy' rating on the company's stock, and the associated price target was lowered to $203.00. The analyst noted that Molina Healthcare, Inc. (NYSE:MOH) continues to effectively manage the medical costs in the challenging environment, mainly in Medicaid, where it is witnessing pressures in behavioral, pharmacy, and inpatient/outpatient care. A doctor in scrubs shaking hands with a patient, representing the healthcare services provided to individuals and families. Molina Healthcare, Inc. (NYSE:MOH) continues to actively work with state partners in order to restore Medicaid rates to appropriate levels. It has considered increased cost trends in the Medicare and Marketplace bids for 2026. Despite challenges, Molina Healthcare, Inc. (NYSE:MOH)'s strategic efforts and adjustments in rate filings reflect growth potential, justifying the analyst's rating. For FY 2025, the Premium revenue is expected to be ~$42 billion, reflecting an increase of ~9% from FY 2024. Molina Healthcare, Inc. (NYSE:MOH) expects its FY 2025 GAAP earnings to be no less than $16.90 per diluted share. Oakmark Funds, advised by Harris Associates, released its Q2 2025 investor letter. Here is what the fund said: 'Molina Healthcare, Inc. (NYSE:MOH) is a leading managed care company. The company is the fourth largest player in managed Medicaid and has consistently delivered industry-leading margins historically. In our view, this is thanks to Molina Healthcare's exceptional management team and culture of operational excellence. Moreover, we think Molina Healthcare has a long runway for growth given its small scale relative to peers and untapped opportunities in their Medicare and Marketplace business segments. Recently, the Medicaid industry has come under substantial pressure due to a challenging redetermination cycle and additional headwinds from legislation under the current administration. This provided the opportunity to, in our view, purchase shares in a best-in-class managed care company at depressed valuation on trough earnings.' While we acknowledge the potential of MOH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock
Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock

Yahoo

time8 hours ago

  • Yahoo

Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock

UnitedHealth Group Incorporated (NYSE:UNH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On August 7, Mizuho analyst Ann Hynes kept her 'Buy' rating, expecting long-term value despite reducing the price objective to $300. The analyst noted that the company has reinstated its 2025 earnings guidance. The analyst believes that pricing pressure and increased medical cost trends will continue into 2026. Furthermore, the analyst also highlighted the underperformance in Optum Health's value-based care and Optum Insight segments. Despite these factors, Hynes opines that UnitedHealth Group Incorporated (NYSE:UNH)'s scale, market position, and diversified business are the key strengths, and believes that the stock's valuation is attractive. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH)'s Q2 2025 revenues increased $12.8 billion YoY to $111.6 billion. This was aided by growth in UnitedHealthcare and Optum. Notably, the Q2 2025 consolidated medical care ratio stood at 89.4%, reflecting an increase of 430 bps YoY. This was mainly because of medical cost trends, which significantly surpassed pricing trends, such as both unit costs and the intensity of services delivered, and the ongoing impacts of Medicare funding reductions. Hotchkis & Wiley, an investment management company, released its Q2 2025 investor letter and mentioned UnitedHealth Group Incorporated (NYSE:UNH). Here is what the fund said: 'UnitedHealth Group Incorporated (NYSE:UNH) is a large US health insurer. Until very recently, UNH traded at a material premium to its peers, reflecting its status as a premium growth stock with momentum. We did not own the stock. However, recent negative headlines, combined with the first earnings miss in 10 years, resulted in a >50% selloff in the company's shares. This decline contributed positively to the strategy's relative performance vs. the index, where UNH was a meaningful weight. We purchased UNH shares after the selloff at what we believe is a compelling valuation.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store